Completed PHASE4 INTERVENTIONAL 2-arm NCT02206256

Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function (OLIVIER)

Sponsor: Medical Center Alkmaar

Interventions Low calorie diet Omega-3 fatty acid capsules

Updated 8 times since 2017 Last updated: Jul 28, 2018 Started: Nov 30, 2014 Primary completion: Nov 30, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02206256, this PHASE4 trial focuses on Morbid Obesity and remains completed. Sponsored by Medical Center Alkmaar, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Aug 2018 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Aug 2018 [monthly]

Unknown Status PHASE4

▶ Show 3 earlier versions

May 2018 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Active Not Recruiting → Unknown Status
Feb 2017 — May 2018 [monthly]

Active Not Recruiting PHASE4
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE4

First recorded

Nov 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical Center Alkmaar

Data source: Medical Center Alkmaar

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beverwijk, Netherlands